OBJECTIVES Based on the specific composition and manufacturing process, the modified release formulations have increased patient compliance, as well as.

Slides:



Advertisements
Similar presentations
6 th Annual Science and Standards Symposium January 16, 2013 Istanbul Determination of Solubility and Permeability in BCS Erika Stippler, Ph.D. Director.
Advertisements

In this study report the results of the effect of pH on the solubility of Nimesulide (BCS poorly soluble drug) in physiological pH. Some drugs having poor.
Waivers of in-vivo BE studies
By Timina Olive Kayaviri Supervisor : Dr. Amugune
Asthma  Most common chronic illness of childhood, affecting approximately 10% children.  Available preventive therapies for persistent asthma include.
Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |1 | Prequalification programme:
Kyiv, TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence.
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health 1 Regulatory Requirements.
Development and validation of an in vitro–in vivo correlation for extended buspirone HCl release tablets Sevgi Takka, Adel Sakr and Arthur Goldberg Journal.
A Seminar on In vitro In vivo Correlation
Bioavailability and Bioequivalence
1 Advisory Committee for Pharmaceutical Science May 3, 2005 Factors Impacting Drug Dissolution and Absorption : Current State of Science Lawrence X. Yu,
Hanoi, WORKSHOP ON PREQUALIFICATION OF ARV: BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence Study Design and Conduct Presented.
World Health Organization
Artemisinin combined medicines, Kampala, February |1 | Training workshop on regulatory requirements for registration of Artemisinin based combined.
Interchangeability and study design Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.
1 TG Dekker – WHO, Malaysia Feb 2005 Comparative dissolution testing and applications World Health Organization Training Workshop on Pharmaceutical Quality,
Documentation of bioequivalence Drs. J. Welink Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October 2009.
Quality by Design Application of Pharmaceutical QbD for Enhancement of the Solubility and Dissolution of a Class II BCS Drug using Polymeric Surfactants.
Establishing Drug release/Dissolution Specifications – QBD Approach Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER Advisory.
ERT 420 BIOPHARMACEUTICAL ENGINEERING Semester 1 Academic Session 2012/2013 HUZAIRY HASSAN School Of Bioprocess Engineering Universiti Malaysia Perlis.
OBJECTIVES The aim was to develop and adequately characterize, through structural analaysis and in-vitro drug release evaluations, new topical semisolid.
OVERVIEW OF DACA BIOEQUIVALENCE REPORT EVALUATION Presented by Solomon Shiferaw 31Augst 2010.
Week 6- Bioavailability and Bioequivalence
PHARMACEUTICS- IV (PHT 414 ) Dr. Shahid Jamil SALMAN BIN ABDUL AZIZ UNIVERSITY COLLEGE OF PHARMACY L /9/2015 Factors Affecting Drug Absorption (Dosage.
Analytical considerations in the dissolution testing of oral modified release products Graham Clarke Bristol-Myers Squibb Moreton, UK The British Pharmaceutical.
COMPARATIVE IN VITRO EVALUATION OF GENERIC CIPROFLOXACIN HYDROCHLORIDE TABLETS IN KENYA BY DANIEL MINYETO U59/81286/2012 Department of Pharmaceutical Chemistry.
A DONE BY: RONO KIPROTICH VICTOR U29/28970/2009 A COMPARATIVE STUDY ON DISSOLUTION PROFILES OF AMOXICILLIN IN AMOXICILLIN CONTAINING CAPSULES AVAILABLE.
1 Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July , 2008 Classification of Orally Disintegrating Tablets Frank O. Holcombe,
Quality control Lecture 1.
WHO Workshop on Assessment of Bioequivalence Data BCS-Biowaivers - Template Dr. Henrike Potthast WHO Workshop on Assessment of.
1 Axcan Public Presentation for the FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting July 23, 2008.
Waiver of In Vivo Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System Ajaz S. Hussain,
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.
Calculating Oral Dosage
Assessment of Interchangeable Multisource Medicines BCS-Biowaivers - Template Dr. Henrike Potthast Training workshop: Assessment of.
WHO Workshop on Prequalification of Medicines Programme, Abu Dhabi, October, 2010 Regulatory principles reflected in practice of WHO PQP Milan Smid,
Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview
WHO Prequalification Programme June 2007 Training Workshop on Dissolution, Pharmaceutical Product Interchangeability and Biopharmaceutical Classification.
Formulation, Characterization of Pellets of Duloxetine Hydrochloride by Extrusion and Spheronization Prof. V. R. Sinha University Institute of Pharmaceutical.
Bioavailability Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University Tobruk, Libya.
Introduction What is a Biowaiver?
Bioavailability and Bioequivalence General concepts and overview
Bioavailability and Bioequivalence L 10,11.  Bioavailability is a measurement of the rate and extent (amount) to which the active ingredient or active.
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.
Interchangeability and study design Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.
Quality Assurance of Medicines under Universal Health Coverage Program by Siriwat Tiptaradol (Presenter) Duangporn Abhigantaphand Sooksri Ungboriboonpisal.
BSC Biowaiver: Components, Requirements and Criteria
*M.Pharmaceutics (3rd Semester), Anand Pharmacy College, Anand.
In vitro - In vivo Correlation
Characterization of the interaction between Lomefloxacin and Certain Gastro-retentive Polymers Amir Ibrahim Mohamed a, Osama A. A. Ahmed b, Amira Osama.
Formulation of an oral dosage form utilizing the properties of cubic liquid crystalline phases of glyceryl monooleate Ref.: European Journal of Pharmaceutics.
1/20 PRESENTED BY BRAHMABHATT BANSARI K. M. PHARM DEPARTMENT OF PHARMACEUTICS AND PHARMACEUTICAL TECHNOLGY L. M. COLLEGE OF PHARMACY.
Definitions and Concepts
Understanding Drug Labels
Vinod P. Shah, Ph.D., FAAPS, FFIP.
- Pharmaceutical Equivalence Study
Introduction What is a Biowaiver?
Introduction of Biopharmaceutics & Pharmacokinetics
Biopharmaceutics of modified release drug products
Dissolution testing and in vitro in vivo correlation of conventional and SR preparations Formulation development and optimization is an ongoing process.
Independent Samples Test Independent Samples Test
Hanneke van der Lee, MD, PhD
BCS based waiver Harmonization
Scientific rationale for EU regulatory expectations concerning product composition in case of Class-I and Class-III medicinal products Dr Ridha BELAIBA.
AIKTC - School of Pharmacy
Selected Bioavailability and Pharmacokinetic Calculations
Biopharmaceuitcs lab 6 In vitro dissolution study of per – oral tablet.
Evaluation of tablet dosage form 5) dissolution
RingCap Technology Mrs. Maria Saifee Associate Professor,
Presentation transcript:

OBJECTIVES Based on the specific composition and manufacturing process, the modified release formulations have increased patient compliance, as well as improved safety and efficacy profiles. Several regulatory guidance are focused on the evaluation of factors susceptible to alter the in-vivo exposure profiles, after oral administration, such as food intake. In 2005, Food and Drug Administration issued an alert letter for healthcare professionals, pointing out a significant dose- dumping effect induced by ethanol consumption on controlled release capsules containing hydromorphone, leading to withdrawal of the product from the market. The in-vitro dissolution tests were adopted as an adequate surrogate to evaluate the changes in product performance, using ethanol in simulated gastric or intestinal fluid without enzymes. The current paper presents the results obtained by applying these tests to modified release formulations containing 100, 150 and 200 mg tramadol hydrochloride. The in-vitro results indicated that the tested modified release formulations containing tramadol hydrochloride were robust with respect to co-administration of ethanol. No dose-dumping effect was observed. The release rates were decreased as the amount of ethanol was increased, probably due to the presence of insoluble excipients and/or inhibited swelling process. No dose dumping effect was observed. The fractions dissolved varied from 25-37% to 17-27% as the concentration of ethanol was increased from 5 to 40%. The rank order of release rates, as well as the kinetic model adequately describing the release process (Korsmeyer-Peppas model, except for Z100 and Z150 formulations, fitted with Higuchi model), were independent on the composition of the release media. The similarity was concluded between each generic product and the reference listed drug, and for different dose strengths of the same product (qualitatively similar, according to the labeled composition). Nevertheless, it seems that increasing the quantity of ethanol in the media reduces the in-vitro differences initially observed in the simulated gastric media. A possible explanation is that several excipients present in the formulation, including macromolecular agents are insoluble in ethanol or the swelling process in inhibited, compared to the aqueous media. In-vitro screening of a potential alcohol-induced dose-dumping effect for modified release formulations containing tramadol hydrochloride Burcea Dragomiroiu George Traian Alexandru 1, Miron Dalia Simona 2, Ginghină Octav 3 *, Lupuliasa Dumitru 4, Bârcă Maria 1, Popa Daniela Elena 1, Ciobanu Anne-Marie 1, Rădulescu Flavian tefan 5 University of Medicine and Pharmacy „Carol Davila” Bucureti 1 Faculty of Pharmacy, Department of Drug Control, 6, Traian Vuia Street, , Bucharest, România 2 Faculty of Pharmacy, Department of Pharmaceutical Physics and Informatics, 6, Traian Vuia Street, , Bucharest, România 3 Faculty of Dental Medicine, Department of Oncological Surgery, „Sf Ioan” Hospital, 13, Vitan-Bârzeti Street, , Bucharest, România 4 Faculty of Pharmacy, Department of Pharmaceutical Technology and Biopharmaceutics, 6, Traian Vuia Street, , Bucharest, România 5 Faculty of Pharmacy, Department of Drug Industry and Pharmaceutical Biotechnologies, 6, Traian Vuia Street, , Bucharest, România Corresponding author: RESULTS AND DISCUSSION CONCLUSIONS REFERENCES Roth W., Setnik B., Zietsch M., Burst A., Breitenbach J., Sellers E., Brennan D., Ethanol effects on drug release from Verapamil Meltrex, an innovative melt extruded formulation. Int J Pharm. 2009;368(1-2):72-5. Smith A.P., Moore T.W., Westenberger B.J., Doub W.H., In vitro dissolution of oral modified-release tablets and capsules in ethanolic media. Int J Pharm. 2010;398(1-2): U.S. FDA alert for healthcare professionals. Alcohol-Palladone TM interaction ACKNOWLEDGEMENT This work was suported by the Sectorial Operational Programme Human Resources (SOP HRD) , financed from the European Social Fund and by the Romanian Gouvernment under the contract number POSDRU/159/1.5/S/133377, „Program de excelenă în cercetare doctorală i postdoctorală” and by PN-II-PT-PCCA MATERIALS AND METHODS The in-vitro dissolution tests were performed on 8 MR solid oral dosage forms using USP apparatus 2 at 50 rpm and 900 ml simulated gastric fluid containing 0, 5, 20 and 40% ethanol (v/v, degassed by filtration under vacuum). Each test was performed on three dosing units, at 37°C. Samples of 5 ml were collected every 15 min for 2 hours. The quantitative analysis of tramadol hydrochloride was performed by a spectrophotometric method (λ max = nm). 0% ethanol 5% ethanol 20% ethanol 40% ethanol